Companies: 10,795·Total market cap: $144.5T
Athira Pharma, Inc.

Athira Pharma, Inc.

ATHANASDAQHealthcare
$6.75
$-0.44(-6.12%)
Market Cap$26621237
P/E Ratio
52W High$8.36
52W Low$2.1955

Athira Pharma, Inc. (ATHA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

atha · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 5 Wall Street analysts in the past 3 months

SellBuy

Hold

5 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
0
Hold
5
Sell
0
Strong Sell
0
Total: 5 · Buy rate: 0.0%

12-Month Price Target

High

$33.00

Consensus

$13.33

+178.3% upside

Low

$3.00

Median: $4 · Last Close: $4.79

The Athira Pharma, Inc. (ATHA) analyst consensus is Hold, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month ATHA price target is $13.33, representing +178.3% upside from the current price of $4.79.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $13 (178.3%)

Consensus Target

$13.33

178.3% upside

High Target

$33

588.9%

Low Target

$3

-37.4%

Current Price

$4.79

as of today

Based on analyst price targets, the ATHA stock price prediction for the next 12 months ranges from $3 to $33. The consensus ATHA price forecast of $13.33 implies 178.3% upside from the current price of $4.79.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$4.555.00%

1-day model range: $4.46–$4.64. Peak: $4.64 (-5.00%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)15.9
MACDNEUTRAL

Moving Averages · ATHA · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$4.71BUY
MA 10$4.96SELL
MA 20$5.71SELL
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $ATHA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$4.79BUY
EMA 10$5.04SELL
EMA 20$5.57SELL
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $ATHA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Mizuho2024-09-19
Downgrade ↓
OutperformNeutral
JMP Securities2024-09-04
Downgrade ↓
Market OutperformMarket Perform
BTIG2024-09-04
Downgrade ↓
BuyNeutral
JMP Securities2024-06-20
Maintains
Market OutperformMarket Outperform
JMP Securities2024-05-16
Maintains
Market OutperformMarket Outperform
JMP Securities2023-08-11
Maintains
OutperformOutperform
Mizuho2023-05-15
Maintains
BuyBuy
BTIG2023-03-30
Maintains
BuyBuy
JMP Securities2022-06-23
Downgrade ↓
Market OutperformMarket Perform
Stifel2022-06-23
Downgrade ↓
BuyHold

Wall Street analysts have recently issued updated ratings on Athira Pharma, Inc. (ATHA) stock. Of the recent 11 rating actions, 0 were upgrades and 6 were downgrades. 5 analysts currently cover ATHA.

Analyst Recommendation Trends

Buy ratings101
Hold ratings03↑ +3
Sell ratings00

ATHA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

Revenue Next Year

$13M

EPS This Year

$-6.24

EPS Next Year

$-4.87

↓ 22.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ATHA EPS of $-6.24 for the current fiscal year, based on estimates from 1 analysts. The ATHA revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ATHA stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ATHA price target is $13.33 (+178.3% upside), with an analyst consensus of Hold.

The ATHA short-term stock prediction for tomorrow is $4.55 (-5.00%).

Athira Pharma, Inc. trades on NASDAQ under the ticker ATHA. The ATHA stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 0% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ATHA forecast · 8 questions

According to 5 Wall Street analysts, the average 12-month ATHA price target is $13.33, with a high forecast of $33.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +178.3% potential upside from the current price of $4.79.

ATHA price targetWhat is ATHA price targetATHA analyst price targetATHA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.